Complement inhibition decreases early fibrogenic events in the lung of septic baboons

Journal of Cellular and Molecular Medicine

Volumn 19, Issue 11, 2015, Pages 2549-2563

  Silasi Mansat, Robert ^a   Zhu, Hua ^a   Georgescu, Constantin ^a   Popescu, Narcis ^a   Keshari, Ravi S ^a   Peer, Glenn ^b   Lupu, Cristina ^a   Taylor, Fletcher B ^a,b   Pereira, Heloise Anne ^b,c   Kinasewitz, Gary ^b   Lambris, John D ^d   Lupu, Florea ^a,b  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Complement; Fibrosis; Lung; Organ failure; Sepsis

Indexed keywords

COMPLEMENT INHIBITOR; COMPSTATIN; CONNECTIVE TISSUE GROWTH FACTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; CYCLOPEPTIDE;

ADULT RESPIRATORY DISTRESS SYNDROME; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CELLULAR STRESS RESPONSE; COLLAGEN SYNTHESIS; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; CONTROLLED STUDY; ELECTRON MICROSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; EXPERIMENTAL SEPSIS; EXTRACTION; GENE EXPRESSION; HYPOXIA; IMMUNOBLOTTING; IMMUNOFLUORESCENCE TEST; LUNG FIBROSIS; MICROARRAY ANALYSIS; MYOFIBROBLAST; NONHUMAN; PAPIO CYNOCEPHALUS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SIGNAL TRANSDUCTION; ANIMAL; BACTEREMIA; DRUG EFFECTS; ESCHERICHIA COLI INFECTIONS; FIBROSIS; GENE EXPRESSION REGULATION; IMMUNOLOGY; LUNG; PATHOLOGY; PATHOPHYSIOLOGY; RESPIRATORY DISTRESS SYNDROME, ADULT;

ANIMALS; BACTEREMIA; COMPLEMENT ACTIVATION; COMPLEMENT INACTIVATING AGENTS; ESCHERICHIA COLI INFECTIONS; FIBROSIS; GENE EXPRESSION REGULATION; LUNG; PEPTIDES, CYCLIC; RESPIRATORY DISTRESS SYNDROME, ADULT;

EID: 84945255749     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12667     Document Type: Article

References (43)

1. Matthay MA, Zemans RL. The acute respiratory distress syndrome: pathogenesis and treatment. Annu Rev Pathol. 2011; 6: 147-63.
2. Araya J, Nishimura SL. Fibrogenic reactions in lung disease. Annu Rev Pathol. 2010; 5: 77-98.
3. Chesnutt AN, Matthay MA, Tibayan FA, et al. Early detection of type III procollagen peptide in acute lung injury. Pathogenetic and prognostic significance. Am J Respir Crit Care Med. 1997; 156: 840-5.
4. Clark JG, Milberg JA, Steinberg KP, et al. Type III procollagen peptide in the adult respiratory distress syndrome. Association of increased peptide levels in bronchoalveolar lavage fluid with increased risk for death. Ann Intern Med. 1995; 122: 17-23.
5. Zapol WM, Trelstad RL, Coffey JW, et al. Pulmonary fibrosis in severe acute respiratory failure. Am Rev Respir Dis. 1979; 119: 547-54.
6. Marshall RP, Bellingan G, Webb S, et al. Fibroproliferation occurs early in the acute respiratory distress syndrome and impacts on outcome. Am J Respir Crit Care Med. 2000; 162: 1783-8.
7. Addis-Lieser E, Kohl J, Chiaramonte MG. Opposing regulatory roles of complement factor 5 in the development of bleomycin-induced pulmonary fibrosis. J Immunol. 2005; 175: 1894-902.
8. Crosby LM, Waters CM. Epithelial repair mechanisms in the lung. Am J Physiol Lung Cell Mol Physiol. 2010; 298: L715-31.
9. Chapman HA. Epithelial-mesenchymal interactions in pulmonary fibrosis. Annu Rev Physiol. 2011; 73: 413-35.
10. Keshari RS, Silasi-Mansat R, Zhu H, et al. Acute lung injury and fibrosis in a baboon model of Escherichia coli sepsis. Am J Respir Cell Mol Biol. 2014; 50: 439-50.
11. Taylor FB Jr, Kinasewitz GT, Lupu F. Pathophysiology, staging and therapy of severe sepsis in baboon models. J Cell Mol Med. 2012; 16: 672-82.
12. Taylor FB Jr, Hack E, Lupu F. Observations on complement activity in the two-stage inflammatory/hemostatic response in the baboon and human models of E. coli sepsis and endotoxemia. Adv Exp Med Biol. 2006; 586: 203-16.
13. Silasi-Mansat R, Zhu H, Popescu NI, et al. Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis. Blood. 2010; 116: 1002-10.
14. Iyer A, Woodruff TM, Wu MC, et al. Inhibition of inflammation and fibrosis by a complement C5a receptor antagonist in DOCA-salt hypertensive rats. J Cardiovasc Pharmacol. 2011; 58: 479-86.
15. Boor P, Konieczny A, Villa L, et al. Complement C5 mediates experimental tubulointerstitial fibrosis. J Am Soc Nephrol. 2007; 18: 1508-15.
16. Katragadda M, Magotti P, Sfyroera G, et al. Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin. J Med Chem. 2006; 49: 4616-22.
17. Sahu A, Kay BK, Lambris JD. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library. J Immunol. 1996; 157: 884-91.
18. Taylor FB Jr, Stearns-Kurosawa DJ, Kurosawa S, et al. The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis. Blood. 2000; 95: 1680-6.
19. Tang H, Ivanciu L, Popescu N, et al. Sepsis-induced coagulation in the baboon lung is associated with decreased tissue factor pathway inhibitor. Am J Pathol. 2007; 171: 1066-77.
20. Lupu C, Westmuckett AD, Peer G, et al. Tissue factor-dependent coagulation is preferentially up-regulated within arterial branching areas in a baboon model of Escherichia coli sepsis. Am J Pathol. 2005; 167: 1161-72.
21. Zhu H, Tang Y, Ivanciu L, et al. Temporal dynamics of gene expression in the lung in a baboon model of E. coli sepsis. BMC Genom. 2007; 8: 58.
22. Gentleman RC, Carey VJ, Bates DM, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004; 5: R80.
23. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003; 4: 249-64.
24. Bolstad BM, Collin F, Simpson KM, et al. Experimental design and low-level analysis of microarray data. Int Rev Neurobiol. 2004; 60: 25-58.
25. Smyth GK. Limma: linear models for microarray data. In: Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W, editors. Bioinformatics and computational biology solutions using R and bioconductor. New York, NY: Springer; 2005. pp. 397-420.
26. Capelson M, Liang Y, Schulte R, et al. Chromatin-bound nuclear pore components regulate gene expression in higher eukaryotes. Cell. 2010; 140: 372-83.
27. Mazzinghi B, Ronconi E, Lazzeri E, et al. Essential but differential role for CXCR4 and CXCR7 in the therapeutic homing of human renal progenitor cells. J Exp Med. 2008; 205: 479-90.
28. Liu X, Das AM, Seideman J, et al. The CC chemokine ligand 2 (CCL2) mediates fibroblast survival through IL-6. Am J Respir Cell Mol Biol. 2007; 37: 121-8.
29. Raghavan M, Marik PE. Management of sepsis during the early "golden hours". J Emerg Med. 2006; 31: 185-99.
30. Meduri GU, Tolley EA, Chinn A, et al. Procollagen types I and III aminoterminal propeptide levels during acute respiratory distress syndrome and in response to methylprednisolone treatment. Am J Respir Crit Care Med. 1998; 158: 1432-41.
31. Deheinzelin D, Jatene FB, Saldiva PH, et al. Upregulation of collagen messenger RNA expression occurs immediately after lung damage. Chest. 1997; 112: 1184-8.
32. Zakynthinos S, Papanikolaou S, Mentzelopoulos S, et al. Procollagen type III aminoterminal propeptide as biomarker of host response in severe sepsis. J Crit Care. 2013; 28: 577-85.
33. Dreisin RB, Schwarz MI, Theofilopoulos AN, et al. Circulating immune complexes in the idiopathic interstitial pneumonias. N Engl J Med. 1978; 298: 353-7.
34. Phan SH, Thrall RS. Inhibition of bleomycin-induced pulmonary fibrosis by cobra venom factor. Am J Pathol. 1982; 107: 25-8.
35. Hillebrandt S, Wasmuth HE, Weiskirchen R, et al. Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans. Nat Genet. 2005; 37: 835-43.
36. Sheerin NS, Sacks SH. Leaked protein and interstitial damage in the kidney: is complement the missing link? Clin Exp Immunol. 2002; 130: 1-3.
37. Hasegawa M, Sato S, Takehara K. Augmented production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1alpha (MIP-1alpha) and MIP-1beta) in patients with systemic sclerosis: MCP-1 and MIP-1alpha may be involved in the development of pulmonary fibrosis. Clin Exp Immunol. 1999; 117: 159-65.
38. Inoshima I, Kuwano K, Hamada N, et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol. 2004; 286: L1038-44.
39. Zhang X, Chen X, Hong Q, et al. TIMP-1 promotes age-related renal fibrosis through upregulating ICAM-1 in human TIMP-1 transgenic mice. J Gerontol A Biol Sci Med Sci. 2006; 61: 1130-43.
40. Lorente L, Martin MM, Labarta L, et al. Matrix metalloproteinase-9, -10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis. Crit Care. 2009; 13: R158.
41. Saftig P, Reiss K. The, "A Disintegrin and Metalloproteases" ADAM10 and ADAM17: novel drug targets with therapeutic potential? Eur J Cell Biol. 2011; 90: 527-35.
42. Quartin AA, Schein RM, Kett DH, et al. Magnitude and duration of the effect of sepsis on survival. Department of Veterans Affairs Systemic Sepsis Cooperative Studies Group. JAMA. 1997; 277: 1058-63.
43. Hall MJ, Williams SN, DeFrances CJ, et al. Inpatient care for septicemia or sepsis: a challenge for patients and hospitals. NCHS data brief. 2011; 62: 1-8.